Navigation Links
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

nd other body tissues. Patients suffering from this disease fatigue easily, and become increasingly less capable of normal activity as they progress through the various stages of the disease. Current standard of care typically involves drug therapy and/or the implantation of a pacemaker and/or defibrillator device to regulate heart function.

ABOUT BIOHEART, INC.

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell, is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth factors.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors inclu
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
9. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
10. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
11. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
(Date:5/29/2015)... 29, 2015  Excite Medical was established by its ... years, Excite Medical, under the leadership of Mr. ... with a solid track record of providing unparalleled service ... distributor base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... has been possible, in large part, due to ...
(Date:5/29/2015)... BRUNSWICK, N.J. , May 29, 2015 ... start-up companies originally funded with investments from Foundation Venture ... research at Bio International 2015 as part of the ... Conference, announced FVCG President James M. Golubieski . ... for the biotechnology industry, will be held in ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Oct. 11 Essentialis, Inc. announced today that the ... has issued U.S. Patent No. 7,799,777 entitled Salts ... The patent claims a novel composition of a polymorph ... lead product, DCCR.  Essentialis has successfully completed phase 2b ...
... 11 Pioneer Surgical Technology, Inc., a leader ... plan to establish a manufacturing and distribution facility ... IDA (Ireland Development Authority) to evaluate potential sites ... facility will support Pioneer,s continued growth in Europe ...
Cached Medicine Technology:Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio 2Pioneer® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland 2
(Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall is happily ... attributes to a lifetime of being health-conscious. She passes on ... of her new book titled “ Cook for Health and ... and Longevity” features a collection of recipes and ideas for ... It is designed to encourage a lifestyle of correct eating ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 Key ... California, is proud to announce their June 2015 featured ... apartment community in San Francisco, Key Housing is helping ... housing in what is one of the tightest apartment ... a plum posting, and understandably anyone who requires temporary ...
(Date:5/30/2015)... 30, 2015 Venus Viva has proven ... large pores, deep wrinkles, stretch marks, pigmentation irregularities, and ... such as Dr. F. Victor Rueckl of Lakes Dermatology ... trials in Las Vegas. This body image solution combines ... system that delivers proven results through a skin heating ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... , BATESVILLE, Ind. , Feb. ... Net revenue decreased 3% year-over-year, due primarily to a lower number of ... net income increased more than 11% during the same period. ... year. Cash flow from operations increased 56.2% to ...
... ... ... Sunquest , a leading provider of healthcare diagnostic information technology and outreach solutions, continues ... take on the additional role of Director of Innovation, the first of two reorganizational ...
... ... Authentically green and actively healthy skincare for babies a ... from "The Very Hungry Caterpillar." The first company to deliver clinically ... the skin, Episencial formulas are made exclusively from all natural ingredients ...
... ... growth of 30% to 31st December 2009. By comparison, growth in the human capital management ... ... Lyle Potgieter CEO of PeopleStreme cited several factors for the growth primarily the appetite for ...
... ... ... for women to get ready for Valentine,s Day ? Why not throw a party ... will be tailgating for Valentine’s Day., , ,Valentine’s Day isn’t just for couples anymore as ...
... ... staff of Vitabot is doing their part to ensure a healthier tomorrow. , , ... (PRWEB) February 4, 2010 -- In the midst of ... to keep afloat. Don,t tell that to the staff at Vitabot. By embracing a ...
Cached Medicine News:Health News:Hillenbrand Reports Results for First Quarter 2010 2Health News:Hillenbrand Reports Results for First Quarter 2010 3Health News:Hillenbrand Reports Results for First Quarter 2010 4Health News:Hillenbrand Reports Results for First Quarter 2010 5Health News:Hillenbrand Reports Results for First Quarter 2010 6Health News:Hillenbrand Reports Results for First Quarter 2010 7Health News:Hillenbrand Reports Results for First Quarter 2010 8Health News:Hillenbrand Reports Results for First Quarter 2010 9Health News:Hillenbrand Reports Results for First Quarter 2010 10Health News:Sunquest Advances Investment in Innovations Team 2Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 2Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 3Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 4Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 5Health News:PeopleStreme Revenue up 30% Year on Year 2Health News:Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research 2Health News:Vitabot Online Nutrition Redefines Corporate Wellness 2Health News:Vitabot Online Nutrition Redefines Corporate Wellness 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: